Advanced Proteome Therapeutics Corporation (APTCF)
Advanced Proteome Therapeutics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Burnaby, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $149,630. On trailing twelve-month figures it carries a trailing P/E of 0.01, a net margin of 0.0%. Its beta of 1.41 implies it has historically moved more than the broad market.
Advanced Proteome Therapeutics Corporation, operating through its subsidiary Advanced Proteome Therapeutics Inc., functions as a biotechnology company based in the United States. Its core business involves the creation and commercialization of a unique platform designed for the chemical modification of protein-based treatments. This proprietary technology is applied across several domains, specifically antibody-drug conjugates, broader protein conjugates, and approaches to immunomodulation. The company's corporate base is in Burnaby, Canada.
Advanced Proteome Therapeutics Corporation is most often compared with the following Healthcare names: